Prognostic significance of cyclooxygenase-2 in osteosarcoma: A meta-analysis

Tumor Biology

Volumn 34, Issue 5, 2013, Pages 2489-2495

  Jiao, Guangjun ^a   Ren, Tingting ^a   Lu, Qunshan ^a   Sun, Yifeng ^a   Lou, Zhiyuan ^a   Peng, Xianbo ^a   Liang, Weimin ^a   Guo, Wei ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Clinical stage; Cyclooxygenase 2; Metastasis; Osteosarcoma; Survival

Indexed keywords

EID: 84885432606     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0998-2     Document Type: Review

References (32)

1. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154-61.
2. Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366-73.
3. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840-55.
4. Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61:303-8.
5. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-11.
6. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7:429-34.
7. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-8.
8. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-16.
9. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998;274:G1061-7.
10. Masi L, Recenti R, Silvestri S, Pinzani P, Pepi M, Paglierani M, et al. Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol. 2007;15:70-6.
11. Ma J, Chen X, Zhong Y, Li D, Xiao Z. Expression and significance of COX-2 and VEGF in osteosarcoma. Shandong Med J. 2011;51:7-9.
12. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237-42.
13. Li Y, Xiao Y, Wang W. Expression of cox-2 and ki-67 in osteosarcoma and their clinical significance. Chin J Gen Pract. 2010;8:274-7.
14. Xu X, Huang G, Liu J, Li L, Luo Y. Expression of PTEN, COX-2 and MMP-9 in osteosarcoma and its clinical significance. J Clin Res. 2010;27:820-3.
15. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res. 2009;467:2932-8.
16. Rodriguez NI, Hoots WK, Koshkina NV, Morales-Arias JA, Arndt CA, Inwards CY, et al. COX-2 expression correlates with survival in patients with osteosarcoma lung metastases. J Pediatr Hematol Oncol. 2008;30:507-12.
17. Geng Y, Wan C, Chen P. Expressions of COX-2 and HF-1α and their relationship with clinicopathologic characteristics of osteosarcoma. Tumor. 2008;28:427-30.
18. Huang J, Shi Y, Xiang Z. The expression of COX-2 in osteosarcoma and its clinical significance. J Med Theor and Prac. 2008;21:1134-6.
19. Zhang X, Cai W. Significance of expression of COX-2 and Fas in cases of osteosarcoma. J Clin Exp Med. 2008;7:45-7.
20. Ouyang Z, Wang S, Kang X, Wang C, Wang J, Guo H. Expression of cyclooxygenase-2 mRNA, cd105mRNA, and the relation between cyclooxygenase-2mRNA and Cd 105mRNA in osteosarcoma. Chin J Bone Tumor Bone Dis. 2007;6:226-32.
21. Liao Y, Li F, Hu X. Expression and clinical significance of OPN and COX-2 in osteosarcoma. Chin-Ger J Clin Oncol. 2007;6:378-82.
22. Zhu Y, Chi Y, Wang Y, Fan G. Study of expression and their relationship of COX-2 and MMP-2 in osteosarcoma. J Pract Oncol. 2005;19:91-4.
23. Jiang Y, Yang S, Liu Y. Expression of cyclooxygenase 2 in osteosarcoma and its significance. Central China Med J. 2004;28:109-10.
24. Dickens DS, Rafal Kozielski R, Leavey PJ, Timmons C, Cripe TP. COX-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol. 2003;25:282-5.
25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
28. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
29. Mascaux C, Martin B, Paesmans M, Berghmans T, Dusart M, Haller A, et al. Has COX-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer. 2006;95:139-45.
30. Jamieson NB, Carter CR, McKay CJ, Oien KA. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17:3316-31.
31. Glover JA, Hughes CM, Cantwell MM, Murray LJ. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer. 2011;105:13-7.
32. Huang M, Chen Q, Xiao J, Liu C, Zhao X. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer. 2013;132:363-73.